Trial Profile
A Pilot Study of Galunisertib (LY2157299) Plus Stereotactic Body Radiotherapy (SBRT) in Patients With Advanced Hepatocellular Carcinoma (HCC)
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 07 Apr 2017
Price :
$35
*
At a glance
- Drugs Galunisertib (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- 31 Mar 2017 Status changed from not yet recruiting to recruiting.
- 20 Mar 2017 New trial record